A new approach for cellular immunotherapy of nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Corey, Khanna, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518531/
https://www.ncbi.nlm.nih.gov/pubmed/23243622
http://dx.doi.org/10.4161/onci.21286
_version_ 1782252570562002944
author Smith, Corey
Khanna, Rajiv
author_facet Smith, Corey
Khanna, Rajiv
author_sort Smith, Corey
collection PubMed
description Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been developed to rapidly generate high frequency EBV-specific T cells to treat patients with refractory or metastatic disease.
format Online
Article
Text
id pubmed-3518531
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185312012-12-14 A new approach for cellular immunotherapy of nasopharyngeal carcinoma Smith, Corey Khanna, Rajiv Oncoimmunology Author's View Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy that is highly prevalent in Southern China and South-East Asia. EBV-targeted immunotherapy remains a goal in the development of novel treatment strategies. A novel adenoviral polyepitope-based immunotherapy has been developed to rapidly generate high frequency EBV-specific T cells to treat patients with refractory or metastatic disease. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518531/ /pubmed/23243622 http://dx.doi.org/10.4161/onci.21286 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Smith, Corey
Khanna, Rajiv
A new approach for cellular immunotherapy of nasopharyngeal carcinoma
title A new approach for cellular immunotherapy of nasopharyngeal carcinoma
title_full A new approach for cellular immunotherapy of nasopharyngeal carcinoma
title_fullStr A new approach for cellular immunotherapy of nasopharyngeal carcinoma
title_full_unstemmed A new approach for cellular immunotherapy of nasopharyngeal carcinoma
title_short A new approach for cellular immunotherapy of nasopharyngeal carcinoma
title_sort new approach for cellular immunotherapy of nasopharyngeal carcinoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518531/
https://www.ncbi.nlm.nih.gov/pubmed/23243622
http://dx.doi.org/10.4161/onci.21286
work_keys_str_mv AT smithcorey anewapproachforcellularimmunotherapyofnasopharyngealcarcinoma
AT khannarajiv anewapproachforcellularimmunotherapyofnasopharyngealcarcinoma
AT smithcorey newapproachforcellularimmunotherapyofnasopharyngealcarcinoma
AT khannarajiv newapproachforcellularimmunotherapyofnasopharyngealcarcinoma

Ejemplares similares